

# CITATION REPORT

List of articles citing

## Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

DOI: 10.1016/j.cell.2015.10.027  
Cell, 2015, 163, 988-98.

**Source:** <https://exaly.com/paper-pdf/62459736/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
298	Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e1005817	7.6	89
297	Advancing translational research with next-generation protein microarrays. <b>2016</b> , 16, 1238-50		21
296	Dimeric FcR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. <b>2016</b> , 197, 1507-16		61
295	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <b>2016</b> , 14, 97-111		29
294	Sequential Infection with Common Pathogens Promotes Human-like Immune Gene Expression and Altered Vaccine Response. <i>Cell Host and Microbe</i> , <b>2016</b> , 19, 713-9	23.4	144
293	Increased Steady-State Memory B Cell Subsets Among High-Risk Participants in an HIV Vaccine Trial. <b>2016</b> , 32, 1143-1148		
292	Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. <b>2016</b> , 353, 1045-1049		107
291	Antibody-Dependent Cellular Cytotoxicity Activity of Effector Cells from HIV-Infected Elite and Viral Controllers. <b>2016</b> , 32, 1079-1088		14
290	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , <b>2016</b> , 90, 10993-11006	6.6	29
289	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. <b>2016</b> , 12, 208-218		45
288	A Functional Role for Antibodies in Tuberculosis. <i>Cell</i> , <b>2016</b> , 167, 433-443.e14	56.2	306
287	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. <i>Journal of Virology</i> , <b>2016</b> , 90, 10362-10378	6.6	15
286	Elimination of HIV-1-infected cells by broadly neutralizing antibodies. <i>Nature Communications</i> , <b>2016</b> , 7, 10844	17.4	150
285	Modulating Antibody Functionality in Infectious Disease and Vaccination. <b>2016</b> , 22, 969-982		54
284	Modeling HIV vaccine trials of the future. <b>2016</b> , 11, 620-627		5
283	Non-neutralizing antibody functions for protection and control HIV in humans and SIV and SHIV in non-human primates. <b>2016</b> , 30, 2551-2553		5
282	New concepts in HIV-1 vaccine development. <b>2016</b> , 41, 39-46		58

281	Cell-targeting antibodies in immunity to Ebola. <b>2016</b> , 74, ftw021		10
280	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. <i>Expert Review of Vaccines</i> , <b>2016</b> , 15, 719-29	5.2	27
279	Humoral Fingerprinting of Immune Responses: Super-Resolution High-Dimensional Serology. <b>2016</b> , 37, 167-169		
278	A systems approach to HIV-1 vaccines. <b>2016</b> , 34, 44-6		2
277	Getting rid of PERVs. <b>2016</b> , 34, 46		3
276	Current views on the potential for development of a HIV vaccine. <b>2017</b> , 17, 295-303		20
275	B-cell responses to HIV infection. <b>2017</b> , 275, 33-48		85
274	Systems serology for evaluation of HIV vaccine trials. <b>2017</b> , 275, 262-270		47
273	Complex immune correlates of protection in HIV-1 vaccine efficacy trials. <b>2017</b> , 275, 245-261		77
272	Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	46
271	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <b>2017</b> , 215, 1255-1263		45
270	Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses. <b>2017</b> , 35, 2582-2591		1
269	Precision immunomedicine. <b>2017</b> , 6, e25		2
268	Latently and uninfected healthcare workers exposed to TB make protective antibodies against. <b>2017</b> , 114, 5023-5028		81
267	Plasticity and Epitope Exposure of the HIV-1 Envelope Trimer. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	25
266	HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection. <b>2017</b> , 21, 158-169		24
265	Adjuvants: tailoring humoral immune responses. <b>2017</b> , 12, 278-284		15
264	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. <b>2017</b> , 33, 410-423		29

263	Maternal immune correlates of protection from human cytomegalovirus transmission to the fetus after primary infection in pregnancy. <b>2017</b> , 27, e1921		26
262	Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial. <b>2017</b> , 24, 195-204		4
261	Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. <b>2017</b> , 214, 2563-2572		13
260	HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV. <b>2017</b> , 3, e00339		3
259	Towards an evidence based approach for the development of adjuvanted vaccines. <b>2017</b> , 47, 93-102		59
258	Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design. <i>Cell Host and Microbe</i> , <b>2017</b> , 22, 193-206	23.4	51
257	A Systems Vaccinology Approach Reveals Temporal Transcriptomic Changes of Immune Responses to the Yellow Fever 17D Vaccine. <b>2017</b> , 199, 1476-1489		19
256	Prospecting for an HIV vaccine. <b>2017</b> , 3, 6		5
255	A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. <b>2017</b> , 26, 2-3		1
254	Highlights from the Third Biennial Strategies for an HIV Cure Meeting. <i>Journal of Virus Eradication</i> , <b>2017</b> , 3, 69-76	2.8	2
253	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 595	8.4	13
252	Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 780	8.4	15
251	Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1033	8.4	10
250	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006148	7.6	36
249	Systems serology: profiling vaccine induced humoral immunity against HIV. <b>2017</b> , 14, 57		35
248	Systems Vaccinology. <b>2017</b> , 101-112		
247	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	33
246	Inclusion of the murine IgG $\beta$ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored <i>Plasmodium vivax</i> multistage vaccine. <b>2018</b> , 36, 2799-2808		5

245	Transcriptomic signatures of NK cells suggest impaired responsiveness in HIV-1 infection and increased activity post-vaccination. <i>Nature Communications</i> , <b>2018</b> , 9, 1212	17.4	24
244	Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. <b>2018</b> , 32, 1207-1217		16
243	High-resolution definition of humoral immune response correlates of effective immunity against HIV. <b>2018</b> , 14, e7881		25
242	Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple <i>Plasmodium falciparum</i> antigens. <b>2018</b> , 455, 41-54		19
241	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	8
240	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. <b>2018</b> , 454, 48-58		10
239	Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors. <b>2018</b> , 32, 443-450		25
238	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	25
237	Passive and active antibody studies in primates to inform HIV vaccines. <i>Expert Review of Vaccines</i> , <b>2018</b> , 17, 127-144	5.2	27
236	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	33
235	HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. <b>2018</b> , 115, 6267-6272		76
234	Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. <b>2018</b> , 457, 41-52		30
233	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? The Importance of Bridging Studies and Species-Independent Correlates of Protection. <b>2018</b> , 10,		21
232	Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity. <b>2018</b> , 10,		5
231	Beyond binding: antibody effector functions in infectious diseases. <i>Nature Reviews Immunology</i> , <b>2018</b> , 18, 46-61	36.5	280
230	Characterization of T-cell immune responses in clinical trials of the candidate RTS,S malaria vaccine. <i>Human Vaccines and Immunotherapeutics</i> , <b>2018</b> , 14, 17-27	4.4	23
229	Anti-HIV-1 antibody-dependent cellular cytotoxicity: is there more to antibodies than neutralization?. <b>2018</b> , 13, 160-166		22
228	Humanized mouse models to study pathophysiology and treatment of HIV infection. <b>2018</b> , 13, 143-151		17

227	Prospects from systems serology research. <b>2018</b> , 153, 279-289		38
226	Personalized vaccinology: A review. <b>2018</b> , 36, 5350-5357		79
225	Rapid detection of multiple respiratory viruses based on microfluidic isothermal amplification and a real-time colorimetric method. <b>2018</b> , 18, 3507-3515		42
224	Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. <i>PLoS ONE</i> , <b>2018</b> , 13, e0194266	3.7	9
223	The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256. <i>PLoS ONE</i> , <b>2018</b> , 13, e0208310	3.7	10
222	Measuring the ability of HIV-specific antibodies to mediate trogocytosis. <b>2018</b> , 463, 71-83		22
221	NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2290	8.4	35
220	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <b>2018</b> , 24, 1590-1598		73
219	Influenza A new pathogen every year. <b>2018</b> , 12, 12-21		3
218	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to $\alpha$ 7. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007278	7.6	21
217	Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients. <b>2018</b> , 90, 1620-1628		11
216	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <b>2018</b> , 215, 1589-1608		23
215	Sustainable vaccine development: a vaccine manufacturer's perspective. <b>2018</b> , 53, 111-118		13
214	Harnessing post-translational modifications for next-generation HIV immunogens. <b>2018</b> , 46, 691-698		2
213	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <b>2018</b> , 5, e366-e378		62
212	Dissecting FcR Regulation through a Multivalent Binding Model. <b>2018</b> , 7, 41-48.e5		12
211	Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?. <b>2018</b> , 15, 52		23
210	CD8 T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication. <b>2018</b> , 15, 46		29

209	Control of Heterologous Simian Immunodeficiency Virus SIV Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	27
208	Advances in HIV-1 Vaccine Development. <b>2018</b> , 10,		43
207	Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	19
206	Big Data: Challenge and Opportunity for Translational and Industrial Research in Healthcare. <b>2018</b> , 5,		6
205	Neonatal Immunization: Rationale, Current State, and Future Prospects. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 532	8.4	29
204	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <b>2018</b> , 392, 232-243		170
203	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	0
202	Immune Correlate-Guided HIV Vaccine Design. <i>Cell Host and Microbe</i> , <b>2018</b> , 24, 25-33	23.4	34
201	HIV Vaccine Efficacy Trials: RV144 and Beyond. <b>2018</b> , 1075, 3-30		3
200	Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. <b>2018</b> , 3,		41
199	IgG3 regulates tissue-like memory B cells in HIV-infected individuals. <i>Nature Immunology</i> , <b>2018</b> , 19, 1001-1012	10.2	19
198	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. <b>2018</b> , 34, 727-738		11
197	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. <b>2018</b> , 15, 58		21
196	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. <b>2018</b> , 462, 74-82		11
195	Rhesus Macaques Vaccinated with , , and Manifest Early Control of SIVmac239 Replication. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	9
194	HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1006987	7.6	49
193	Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	6
192	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. <b>2019</b> , 9,		8

191	V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	8
190	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. <i>Cell Reports</i> , <b>2019</b> , 28, 877-895.e6	10.6	21
189	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. <i>Vaccines</i> , <b>2019</b> , 7,	5.3	9
188	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	24
187	A Sample-Sparing Multiplexed ADCP Assay. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1851	8.4	17
186	Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC. <b>2019</b> , 105, 551-563		7
185	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. <b>2019</b> , 15, e8747		10
184	Outflanking immunodominance to target subdominant broadly neutralizing epitopes. <b>2019</b> , 116, 13474-13479		40
183	Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	5
182	Role of the Microbiota in the Modulation of Vaccine Immune Responses. <b>2019</b> , 10, 1305		50
181	Quantifying Anti-HIV Envelope-Specific Antibodies in Plasma from HIV Infected Individuals. <b>2019</b> , 11,		6
180	Dysfunctional peripheral T follicular helper cells dominate in people with impaired influenza vaccine responses: Results from the FLORAH study. <i>PLoS Biology</i> , <b>2019</b> , 17, e3000257	9.7	22
179	IgG and FcγReceptors in Intestinal Immunity and Inflammation. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 805	8.4	37
178	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1025	8.4	22
177	The Antibodiome-Mapping the Humoral Immune Response to HIV. <b>2019</b> , 16, 169-179		6
176	Antibody-Dependent Cellular Phagocytosis in Antiviral Immune Responses. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 332	8.4	72
175	Serum IgM Glycosylation Associated with Tuberculosis Infection in Mice. <b>2019</b> , 4,		11
174	Role of IgG3 in Infectious Diseases. <b>2019</b> , 40, 197-211		56



173	Robust latent-variable interpretation of in vivo regression models by nested resampling. <b>2019</b> , 9, 19671		1
172	Terminal Effector CD8 T Cells Defined by an IKZF2IL-7R Transcriptional Signature Express FcR1IA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity. <b>2019</b> , 203, 2210-2221		13
171	An Inflammatory Story: Antibodies in Tuberculosis Comorbidities. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2848.4		10
170	Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2968	8.4	26
169	IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1008064	7.6	25
168	B-cell abnormalities in HIV-1 infection: roles for IgG3 and T-bet. <b>2019</b> , 14, 240-245		9
167	Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV. <b>2019</b> , 14, 309-317		19
166	Systems serology for decoding infection and vaccine-induced antibody responses to HIV-1. <b>2019</b> , 14, 253-264		6
165	Neutralizing antibodies for HIV-1 prevention. <b>2019</b> , 14, 318-324		23
164	Correlates of broadly neutralizing antibody development. <b>2019</b> , 14, 279-285		5
163	Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. <b>2019</b> , 37, 863-868		41
162	Systems vaccinology and big data in the vaccine development chain. <b>2019</b> , 156, 33-46		36
161	Identification and Functional Characterization of a Novel Fc Gamma-Binding Glycoprotein in Rhesus Cytomegalovirus. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	8
160	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. <b>2020</b> , 221, 756-765		2
159	Functional antibodies as immunological endpoints to evaluate protective immunity against. <i>Human Vaccines and Immunotherapeutics</i> , <b>2020</b> , 16, 197-205	4.4	8
158	Systems immunology reveals a linked IgG3-C4 response in patients with acute rheumatic fever. <b>2020</b> , 98, 12-21		4
157	Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology. <b>2020</b> , 38, 187-193		4
156	Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques. <i>Cell</i> , <b>2020</b> , 183, 185-196.e14	56.2	11

155	Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV. <b>2020</b> , 15, 316-323		4
154	Why and How Vaccines Work. <i>Cell</i> , <b>2020</b> , 183, 290-295	56.2	44
153	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. <b>2020</b> , 586, 583-588		550
152	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008868	6.8	5
151	The Quantitative Assessment of the Secreted IgG Repertoire after Recall to Evaluate the Quality of Immunizations. <b>2020</b> , 205, 1176-1184		6
150	The continued advance of vaccine adjuvants - We can work it out <b>2020</b> , 50, 101426		26
149	Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 583820	8.4	2
148	Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1274	8.4	1
147	Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	46
146	Deep phenotypic characterization of immunization-induced antibacterial IgG repertoires in mice using a single-antibody bioassay. <b>2020</b> , 3, 614		1
145	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. <b>2020</b> , 26, 1694-1700		176
144	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1008764	7.6	20
143	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , <b>2020</b> , 33, 108502	10.6	10
142	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. <i>Cell</i> , <b>2020</b> , 183, 1508-1518	5.2	134
141	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. <b>2020</b> , 369, 812-817		592
140	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. <b>2020</b> , 369, 806-811		748
139	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 984	8.4	6
138	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. <i>Journal of Virology</i> , <b>2020</b> , 94,	6.6	4

137	Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 1141	8.4	10
136	From Bivariate to Multivariate Analysis of Cytometric Data: Overview of Computational Methods and Their Application in Vaccination Studies. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	5
135	Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003038	11.6	14
134	Persistence of vaccine-elicited immune response up to 14 years post-HIV gp120-NefTat/AS01 vaccination. <b>2020</b> , 38, 1678-1689		2
133	Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	1
132	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <b>2020</b> , 38, 673-703		40
131	HIV vaccinology: 2021 update. <b>2021</b> , 51, 101470		3
130	Compromised SARS-CoV-2-specific placental antibody transfer. <i>Cell</i> , <b>2021</b> , 184, 628-642.e10	56.2	72
129	A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors.		0
128	Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 657424	8.4	0
127	Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009363	7.6	5
126	Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques. <i>Nature Communications</i> , <b>2021</b> , 12, 1474	17.4	7
125	Immunogenicity of the Ad26.COVS Vaccine for COVID-19. <b>2021</b> , 325, 1535-1544		139
124	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. <i>Nature Communications</i> , <b>2021</b> , 12, 2037	17.4	42
123	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , <b>2021</b> , 12,	7.8	4
122	Robust IgM responses following vaccination are associated with prevention of Mycobacterium tuberculosis infection in macaques.		2
121	Immunoprofiling Correlates of Protection Against SHIV Infection in Adjuvanted HIV-1 Pox-Protein Vaccinated Rhesus Macaques. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 625030	8.4	1
120	Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset. <i>Med</i> , <b>2021</b> , 2, 682-688.e4	31.7	56

119	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <b>2021</b> , 596, 423-427		22
118	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , <b>2021</b> , 2, 701-719.e19	31.7	10
117	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <b>2021</b> , 596, 268-272		122
116	Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination. <b>2021</b> , 35, 1895-1905		1
115	Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
114	Immune age and biological age as determinants of vaccine responsiveness among elderly populations: the Human Immunomics Initiative research program. <b>2021</b> , 36, 753-762		3
113	RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infection. <b>2021</b> , 7, veab057		1
112	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 679973	8.4	3
111	Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection. <b>2021</b> , 495, 113087		2
110	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. <i>Vaccines</i> , <b>2021</b> , 9,	5.3	0
109	Mixed Origins: HIV gp120-specific memory develops from pre-existing memory and naïve B cells following vaccination in humans.		
108	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. <b>2021</b> , 2, 100386		3
107	Tensor-structured decomposition improves systems serology analysis. <b>2021</b> , 17, e10243		2
106	Antibody effector analysis of prime versus prime-boost immunizations with a recombinant measles-vectored chikungunya virus vaccine. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	1
105	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	22
104	Structured decomposition improves systems serology prediction and interpretation.		0
103	High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
102	Dengue Vaccines: The Promise and Pitfalls of Antibody-Mediated Protection. <i>Cell Host and Microbe</i> , <b>2021</b> , 29, 13-22	23.4	3

101	Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. <b>2020</b> , 1,		4
100	Correlates of protection against SARS-CoV-2 in rhesus macaques. <b>2021</b> , 590, 630-634		498
99	Vi-specific serological correlates of protection for typhoid fever. <b>2021</b> , 218,		11
98	The pentameric complex of human Cytomegalovirus: cell tropism, virus dissemination, immune response and vaccine development. <i>Journal of General Virology</i> , <b>2017</b> , 98, 2215-2234	4.9	22
97	High antibody titres induced by protein subunit vaccines against Buruli ulcer using Mycobacterium ulcerans antigens Hsp18 and MUL_3720.		1
96	Distinct systems serology features in children, elderly and COVID patients.		15
95	High-resolution mapping of the neutralizing and binding specificities of polyclonal rabbit serum elicited by HIV Env trimer immunization.		0
94	HCMV glycoprotein B subunit vaccine efficacy was mediated by non-neutralizing antibody effector functions.		2
93	Outflanking Immunodominance to Target Subdominant Broadly Neutralizing Epitopes.		1
92	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	11
91	IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	1
90	Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG. <i>JCI Insight</i> , <b>2017</b> , 2, e88226	9.9	10
89	Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , <b>2016</b> , 1, e88522	9.9	6
88	Reevaluation of immune activation in the era of cART and an aging HIV-infected population. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	27
87	DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4769-4785	15.9	16
86	Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 662-672	15.9	25
85	Simplified steps to heterologous prime-boost HIV vaccine development?. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4572-4573	15.9	1
84	Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003117	11.6	2

83	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226803	3.7	10
82	Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. <i>PLoS Pathogens</i> , <b>2016</b> , 12, e10054566	5.6	88
81	RV144 HIV-1 vaccination impacts post-infection antibody responses. <i>PLoS Pathogens</i> , <b>2020</b> , 16, e1009107	1.6	3
80	High antibody titres induced by protein subunit vaccines using antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice. <i>PeerJ</i> , <b>2020</b> , 8, e9659	3.1	5
79	Validation of Isolate Stability Status and in silico Characterization of SARS-COV 2 Partial CdsRdRP Gene Sequences. <i>Trends in Bioinformatics</i> , <b>2021</b> , 14, 13-27	0	
78	Building a better antibody through the Fc: advances and challenges in harnessing antibody Fc effector functions for antiviral protection. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-17	4.4	3
77	A general model of multivalent binding with ligands of heterotypic subunits and multiple surface receptors. <i>Mathematical Biosciences</i> , <b>2021</b> , 342, 108714	3.9	0
76	HIV Vaccine Approaches. 1-11		
75	Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples.		
74	Dissecting FcR Regulation Through a Multivalent Binding Model.		
73	Robust latent-variable interpretation of in vivo regression models by nested resampling.		
72	SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines.		
71	Host Variation in Interferon, MHC Class I, Glycosylation, and Viral Transcription Genes Predict HIV Persistence.		1
70	Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA. <i>Journal of Virus Eradication</i> , <b>2017</b> , 3, 69-76	2.8	2
69	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , <b>2021</b> , 12, 6853	17.4	3
68	Targeting BMI-1 in B cells restores effective humoral immune responses and controls chronic viral infection. <i>Nature Immunology</i> , <b>2021</b> ,	19.1	0
67	Engaging innate immunity in HIV-1 cure strategies. <i>Nature Reviews Immunology</i> , <b>2021</b> ,	36.5	2
66	Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1010016	7.6	1

65	Delayed fractional dosing with RTS,S/AS01 improves humoral immunity to malaria via a balance of polyfunctional NANP6- and PF16-specific antibodies.. <i>Med</i> , <b>2021</b> , 2, 1269-1286.e9	31.7	0
64	Serological and cellular inflammatory signatures in end-stage kidney disease and latent tuberculosis. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1355	6.8	1
63	Serological Markers of SARS-CoV-2 Reinfection.. <i>MBio</i> , <b>2022</b> , e0214121	7.8	1
62	Upper and lower respiratory tract correlates of protection against respiratory syncytial virus following vaccination of nonhuman primates. <i>Cell Host and Microbe</i> , <b>2021</b> ,	23.4	2
61	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.. <i>PLoS Pathogens</i> , <b>2022</b> , 18, e1010183	7.6	2
60	Dissecting Fc signatures of protection in neonates following maternal influenza vaccination in a placebo-controlled trial.. <i>Cell Reports</i> , <b>2022</b> , 38, 110337	10.6	1
59	A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy.		0
58	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcR Complex Formation After Vaccination.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 820148	8.4	
57	Altered maternal antibody profiles in women with HIV drive changes in transplacental antibody transfer.. <i>Clinical Infectious Diseases</i> , <b>2022</b> ,	11.6	0
56	A homologous or variant booster vaccine after Ad26.COVS immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.. <i>Science Translational Medicine</i> , <b>2022</b> , eabm4996	17.5	1
55	Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.. <i>Journal of Virology</i> , <b>2022</b> , e0003422	6.6	1
54	"World in motion" - emulsion adjuvants rising to meet the pandemic challenges.. <i>Npj Vaccines</i> , <b>2021</b> , 6, 158	9.5	4
53	FcR Genetic Variation and HIV-1 Vaccine Efficacy: Context And Considerations.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 788203	8.4	0
52	Image_1.TIF. <b>2020</b> ,		
51	Image_2.TIF. <b>2020</b> ,		
50	Image_3.TIF. <b>2020</b> ,		
49	Image_4.TIF. <b>2020</b> ,		
48	Image_5.TIF. <b>2020</b> ,		

47 Image\_6.TIF. 2020,

46 Image\_1.TIFF. 2020,

45 Image\_2.TIFF. 2020,

44 Image\_3.TIFF. 2020,

43 Image\_4.TIFF. 2020,

42 Image\_5.TIFF. 2020,

41 Presentation\_1.pdf. 2020,

40 Table\_1.DOCX. 2020,

39 Table\_2.docx. 2020,

38 Table\_3.DOCX. 2020,

37 Table\_4.DOCX. 2020,

36 Table\_5.DOCX. 2020,

35 Table\_6.DOCX. 2020,

34 Data\_Sheet\_1.PDF. 2020,

33 Table\_1.DOCX. 2019,

32 Delayed booster dosing improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. ○

31 Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates.. *PLoS Biology*, 2022, 20, e3001609 9:7 ○

30 Fc receptors and the diversity of antibody responses to HIV infection and vaccination. *Genes and Immunity*, 4:4



29	Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development. <i>Annual Review of Virology</i> , <b>2022</b> , 9,	14.6	0
28	Delayed Booster Dosing Improves Human Antigen-Specific IG and B Cell Responses to the RH5.1/AS01 &sub&gt;B&sub&gt;; Malaria Vaccine. <i>SSRN Electronic Journal</i> ,	1	
27	Antibody Fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection. <i>Science Translational Medicine</i> , <b>2022</b> , 14,	17.5	1
26	Virology and immune dynamics reveal high household transmission of ancestral SARS-CoV-2 strain. <i>Pediatric Allergy and Immunology</i> , <b>2022</b> , 33,	4.2	2
25	The omics strategy: the use of systems vaccinology to characterize immune responses to childhood immunization. <i>Expert Review of Vaccines</i> , 1-10	5.2	0
24	Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection. <i>ELife</i> , 11,	8.9	0
23	Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD variants.		0
22	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. <i>Vaccines</i> , <b>2022</b> , 10, 1069	5.3	1
21	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. <b>2022</b> , 5, e2226335		2
20	Polysaccharide and conjugate vaccines to <i>Streptococcus pneumoniae</i> generate distinct humoral responses. <b>2022</b> , 14,		0
19	BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age.		
18	Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. <b>2022</b> , 84, 104271		0
17	Covid-19 Vaccines ¶Immunity, Variants, Boosters. <b>2022</b> , 387, 1011-1020		9
16	Selective transfer of maternal antibodies in preterm and fullterm children. <b>2022</b> , 12,		0
15	BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age. <b>2022</b> , 111544		0
14	Human natural killer cells confer protection against HIV-1 infection in humanized mice.		1
13	Nucleocapsid-specific antibody function is associated with therapeutic benefit from Covid-19 Convalescent plasma therapy. <b>2022</b> , 100811		0
12	Fc mediated pan-sarbecovirus protection after alphavirus vector vaccination.		0

- 11 Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. ○
- 10 Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. **2023**, 8, 1
- 9 Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates. **2023**, 42, 112402 ○
- 8 Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans. ○
- 7 Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates. ○
- 6 Fibroblast, Epithelial and Endothelial Cell-Derived Human Cytomegalovirus Strains Display Distinct Neutralizing Antibody Responses and Varying Levels of gH/gL Complexes. **2023**, 24, 4417 ○
- 5 New-age vaccine adjuvants, their development, and future perspective. 14, ○
- 4 Differences in HPV-specific antibody Fc-effector functions following Gardasil<sup>®</sup> and Cervarix<sup>®</sup> vaccination. **2023**, 8, ○
- 3 Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design. **2023**, 8, ○
- 2 Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. **2023**, 42, 112326 ○
- 1 Functional assays to evaluate antibody-mediated responses against Shigella: a review. 13, ○